Key Highlights
- Repligen plans to acquire BioLife Solutions through a combination of cash and stock valued at approximately $1.5 billion
- Shareholders of BioLife will receive $11.25 in cash alongside 0.1442 shares of RGEN stock per share — representing a 6.2% premium over the previous closing price, with a total valuation of $31 per share
- The transaction is projected to contribute a minimum of $0.05 to EPS in the first year and $0.25 in the second year
- Repligen anticipates realizing no less than $20 million in cost synergies during year one, escalating to $30 million in the second year
- The transaction is slated for completion in the fourth quarter of 2026, subject to necessary regulatory clearances and shareholder consent
Shares of Repligen (RGEN) declined approximately 5.84% during Wednesday’s trading session following the company’s announcement of its plan to purchase BioLife Solutions (BLFS) in a transaction valued at roughly $1.5 billion.
The transaction framework consists of 64% Repligen equity and 36% cash consideration. Shareholders of BioLife will be entitled to $11.25 cash per share along with 0.1442 shares of RGEN for every share held. This arrangement establishes a total consideration of $31 per share — reflecting a 6.2% premium above BioLife’s most recent closing price.
The boards of directors of both companies have provided unanimous approval for the merger. Completion of the transaction is anticipated during the fourth quarter of 2026, contingent upon receiving necessary approvals from shareholders and regulatory authorities.
According to Repligen’s announcement, the acquisition will enhance adjusted earnings per share by no less than $0.05 during the first year and a minimum of $0.25 in the second year. The company intends to finance the cash component utilizing existing cash reserves and anticipates maintaining over $300 million in pro forma cash balances upon transaction completion.
Management forecasts achieving no less than $20 million in cost synergy benefits during the initial year post-closing, expanding to a minimum of $30 million in the subsequent year. These anticipated savings are expected to stem from reducing public-company administrative costs, operational efficiencies in general and administrative functions, and improvements in supply-chain management.
Strategic Assets Being Acquired
BioLife’s flagship offering centers on its biopreservation media technology, headlined by CryoStor. This product suite currently supports 18 therapies that have received commercial approval and is utilized in the vast majority of commercially sponsored cell-based therapy clinical trials conducted in the United States.
The acquisition also encompasses BioLife’s portfolio of cell-processing technologies and a high-margin consumables operation generating recurring revenue streams. According to Repligen, the combined entity will enhance its ability to serve the cell therapy market more comprehensively, including strengthened presence across the Asia Pacific region.
Prior to this acquisition agreement, BioLife had undertaken strategic portfolio refinement initiatives. In October 2025, the company divested its evo cold-chain logistics division for $25.5 million, concentrating resources on its cell and gene therapy technology offerings.
Latest Financial Results
Repligen disclosed preliminary second quarter 2026 revenue expansion of approximately 12% to 13% on an organic growth basis. BioLife’s preliminary second quarter revenue demonstrated approximately 21% year-over-year growth.
This transaction follows Tuesday’s remarks from Danaher indicating a resurgence in bioprocessing market demand, as biotechnology and pharmaceutical companies are ramping up capital expenditures following an extended period of subdued research investment and inventory destocking.
The announcement arrives roughly one month subsequent to German pharmaceutical company Merck KGaA’s unveiling of an $11.3 billion agreement to purchase Bio-Techne, another supplier of tools for pharmaceutical development.
Repligen’s Chief Executive Officer Olivier Loeillot characterized BioLife’s product portfolio as “highly differentiated” and noted that the purchase enhances the company’s existing presence in cell therapy. BioLife’s CEO Roderick de Greef described Repligen as an “ideal partner” citing its worldwide commercial infrastructure and complementary technology platforms.
RGEN traded down 5.84% while BLFS gained 0.34% during early Wednesday market activity.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
